Alkermes plc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
We lease an approximately 14,600 square foot corporate office space in Dublin, Ireland, which is our corporate headquarters. This lease expires in January 2027 and does not include an additional tenant option to further extend the term.
In December 2025, we entered into a lease agreement for an approximately 6,675 square foot corporate office space in Athlone, Ireland. The initial term of the lease commenced on January 1, 2026, expires on December 31, 2030 and includes an option to extend for an additional five-year period.
We lease an approximately 231,000 square foot corporate office and R&D center in Waltham, Massachusetts. This lease, which commenced in January 2020, expires in 2035 and includes a tenant option to extend the term for an additional ten-year period.
We lease an approximately 7,000 square foot corporate office and administrative space in Washington, DC. This lease expires in 2029 and includes a tenant option to extend the term for an additional five-year period.
We lease an approximately 17,065 square foot corporate office and administrative space in Chesterfield, Missouri. This lease expires in 2029 and includes a tenant option to extend the term for an additional three-year period.
We own an approximately 375,000 square foot manufacturing facility in Wilmington, Ohio.
We believe that our current facilities are suitable and adequate for our current and near-term preclinical, clinical and commercial requirements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.